Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity.

Functional connectivity Global brain connectivity Psilocybin Receptor gene expression Serotonin fMRI

Journal

Biological psychiatry
ISSN: 1873-2402
Titre abrégé: Biol Psychiatry
Pays: United States
ID NLM: 0213264

Informations de publication

Date de publication:
15 07 2020
Historique:
received: 21 06 2019
revised: 23 11 2019
accepted: 27 12 2019
pubmed: 1 3 2020
medline: 12 1 2021
entrez: 1 3 2020
Statut: ppublish

Résumé

The use of psilocybin in scientific and experimental clinical contexts has triggered renewed interest in the mechanism of action of psychedelics. However, its time-dependent systems-level neurobiology remains sparsely investigated in humans. We conducted a double-blind, randomized, counterbalanced, crossover study comprising 23 healthy human participants who received placebo and 0.2 mg/kg of psilocybin orally on 2 different test days. Participants underwent magnetic resonance imaging at 3 time points between administration and peak effects: 20 minutes, 40 minutes, and 70 minutes after administration. Resting-state functional connectivity was quantified via a data-driven global brain connectivity method and compared with cortical gene expression maps. Psilocybin reduced associative, but concurrently increased sensory, brain-wide connectivity. This pattern emerged over time from administration to peak effects. Furthermore, we showed that baseline connectivity is associated with the extent of psilocybin-induced changes in functional connectivity. Lastly, psilocybin-induced changes correlated in a time-dependent manner with spatial gene expression patterns of the 5-HT These results suggest that the integration of functional connectivity in sensory regions and the disintegration in associative regions may underlie the psychedelic state and pinpoint the critical role of the serotonin 2A and 1A receptor systems. Furthermore, baseline connectivity may represent a predictive marker of the magnitude of changes induced by psilocybin and may therefore contribute to a personalized medicine approach within the potential framework of psychedelic treatment.

Sections du résumé

BACKGROUND
The use of psilocybin in scientific and experimental clinical contexts has triggered renewed interest in the mechanism of action of psychedelics. However, its time-dependent systems-level neurobiology remains sparsely investigated in humans.
METHODS
We conducted a double-blind, randomized, counterbalanced, crossover study comprising 23 healthy human participants who received placebo and 0.2 mg/kg of psilocybin orally on 2 different test days. Participants underwent magnetic resonance imaging at 3 time points between administration and peak effects: 20 minutes, 40 minutes, and 70 minutes after administration. Resting-state functional connectivity was quantified via a data-driven global brain connectivity method and compared with cortical gene expression maps.
RESULTS
Psilocybin reduced associative, but concurrently increased sensory, brain-wide connectivity. This pattern emerged over time from administration to peak effects. Furthermore, we showed that baseline connectivity is associated with the extent of psilocybin-induced changes in functional connectivity. Lastly, psilocybin-induced changes correlated in a time-dependent manner with spatial gene expression patterns of the 5-HT
CONCLUSIONS
These results suggest that the integration of functional connectivity in sensory regions and the disintegration in associative regions may underlie the psychedelic state and pinpoint the critical role of the serotonin 2A and 1A receptor systems. Furthermore, baseline connectivity may represent a predictive marker of the magnitude of changes induced by psilocybin and may therefore contribute to a personalized medicine approach within the potential framework of psychedelic treatment.

Identifiants

pubmed: 32111343
pii: S0006-3223(20)30005-6
doi: 10.1016/j.biopsych.2019.12.027
pii:
doi:

Substances chimiques

Hallucinogens 0
Psilocybin 2RV7212BP0

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

197-207

Subventions

Organisme : NIMH NIH HHS
ID : R01 MH112746
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2020 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Auteurs

Katrin H Preller (KH)

Neuropsychopharmacology and Brain Imaging Unit, University Hospital for Psychiatry Zurich, Zurich, Switzerland; Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut. Electronic address: preller@bli.uzh.ch.

Patricia Duerler (P)

Neuropsychopharmacology and Brain Imaging Unit, University Hospital for Psychiatry Zurich, Zurich, Switzerland.

Joshua B Burt (JB)

Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut; Department of Physics, Yale University, New Haven, Connecticut.

Jie Lisa Ji (JL)

Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.

Brendan Adkinson (B)

Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.

Philipp Stämpfli (P)

Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital for Psychiatry Zurich, Zurich, Switzerland.

Erich Seifritz (E)

Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital for Psychiatry Zurich, Zurich, Switzerland.

Grega Repovš (G)

Mind and Brain Laboratory, Department of Psychology, University of Ljubljana, Ljubljana, Slovenia.

John H Krystal (JH)

Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.

John D Murray (JD)

Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut; Department of Neuroscience, Yale University School of Medicine, New Haven, Connecticut; Department of Physics, Yale University, New Haven, Connecticut.

Alan Anticevic (A)

Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.

Franz X Vollenweider (FX)

Neuropsychopharmacology and Brain Imaging Unit, University Hospital for Psychiatry Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH